Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

• Vandana Sachdev,
• Amita Kulshreshtha,
• Julia W Cohen,
• Doug R Rosing,
• Stanislav Sidenko,
• Cindy Delbrook,
• Brandon Wiley

Affiliations

Vandana Sachdev

National Heart, Lung, and Blood Institute/Cardiovascular Branch, National Institutes of Health, Bethesda, Maryland, USA

Amita Kulshreshtha

National Cancer Institute/Pediatric Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA

Julia W Cohen

National Cancer Institute/Pediatric Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA

Doug R Rosing

National Heart, Lung, and Blood Institute/Cardiovascular Branch, National Institutes of Health, Bethesda, Maryland, USA

Stanislav Sidenko

National Heart, Lung, and Blood Institute/Cardiovascular Branch, National Institutes of Health, Bethesda, Maryland, USA

Cindy Delbrook

National Cancer Institute/Pediatric Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA

Brandon Wiley

Critical Care Medicine Department, National Institutes of Health, Bethesda, Maryland, USA